Ivermectin is proven to prevent and treat covid effectively in meta analyses of multinational implementations. Top doctors from FLCCC believe it can end the pandemic, but no governmental health agency has created a study or informed the public. In fact, they seem dead set against it, and the two studies on the horizon are beset by conflicts of interest. Why is this?
Could it be that would eliminate the Emergency Use Authorization and stop the payoff for vaccines? Because it is is off patent and pennies per dose, thus eliminating any profit scheme?
The debate rages on, but the facts are clear, Ivermectin stops covid, both as a prophylactic (yes, a condom….) and as a treatment.
Here is the latest on the science, with a touch of insight into the swindle. For more on that, read our text blog.
Best ivermectin meta analysis
Ivermectin for Prevention and Treatment of COVID-19 Infection
A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
https://journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx
Background
The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested ...in numerous clinical trials.
A 2018 application for ivermectin use for scabies gives a direct cost of $2.90 for 100 12-mg tablets.
Most trials were registered, self-funded, and undertaken by clinicians
We assessed
Efficacy of ivermectin treatment in reducing mortality
Chemoprophylaxis
Data sources
Databases up to April 25, 2021
Sifted for studies, extracted data, and assessed risk of bias
Meta-analyses were conducted and certainty of the evidence was assessed
GRADE approach
https://training.cochrane.org/grade-approach
https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/
GRADE (Grading of Recommendations, Assessment, Development and Evaluations)
Reproducible and transparent framework for grading certainty in evidence
100 organisations worldwide officially endorsing GRADE
GRADE has four levels of evidence, certainty in evidence
very low
low
moderate
high
Decreasing confidence
Risk of bias
Imprecision
Inconsistency
Indirectness
Publication bias
Increases confidence
Very large magnitude of effect
Clear dose-response gradient
Residual confounding is likely to decrease rather than increase the magnitude of effect
Data sources
24 randomized controlled trials
N = 3,406 participants
Ivermectin reduced risk of death compared with no ivermectin
Meta-analysis of 15 trials (n = 2,438)
Average risk ratio 0.38
Moderate-certainty evidence
(Confirmed using DerSimonian–Laird method and Biggerstaff–Tweedie method)
Ivermectin verses no ivermectin in hospital patients
Ivermectin, 2.3%
No ivermectin, 7.8%
Ivermectin prophylaxis reduced COVID-19 infection
3 trials, n = 738
Average reduction 86%
Low-certainty evidence
(due to study design limitations and few included trials)
Clearly favored ivermectin use
improvement
deterioration
Severe adverse events
Rare among treatment trials
Evidence of no difference was assessed as low certainty
Conclusions
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin.
Using ivermectin early in the clinical course may reduce numbers progressing
to severe disease.
The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Current NIH recommendations
https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/
there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19
The sample size of most of the trials was small
Various doses and schedules of ivermectin were used
Some of the randomized controlled trials were open-label
Patients received various concomitant (confounding) medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids)
The severity of COVID-19 in the study participants was not always well described
The study outcome measures were not always clearly defined
Ivermectin for preventing and treating COVID‐19 (April, 2021)
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017/full?highlightAbstract=ivermectin%7CcovidShow More
Best ivermectin meta analysis
Ivermectin for Prevention and Treatment of COVID-19 Infection A ...
Ivermectin for Prevention and Treatment of COVID-19 Infection
A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
https://journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx
Background
The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested ...in numerous clinical trials.
A 2018 application for ivermectin use for scabies gives a direct cost of $2.90 for 100 12-mg tablets.
Most trials were registered, self-funded, and undertaken by clinicians
We assessed
Efficacy of ivermectin treatment in reducing mortality
Chemoprophylaxis
Data sources
Databases up to April 25, 2021
Sifted for studies, extracted data, and assessed risk of bias
Meta-analyses were conducted and certainty of the evidence was assessed
GRADE approach
https://training.cochrane.org/grade-approach
https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/
GRADE (Grading of Recommendations, Assessment, Development and Evaluations)
Reproducible and transparent framework for grading certainty in evidence
100 organisations worldwide officially endorsing GRADE
GRADE has four levels of evidence, certainty in evidence
very low
low
moderate
high
Decreasing confidence
Risk of bias
Imprecision
Inconsistency
Indirectness
Publication bias
Increases confidence
Very large magnitude of effect
Clear dose-response gradient
Residual confounding is likely to decrease rather than increase the magnitude of effect
Data sources
24 randomized controlled trials
N = 3,406 participants
Ivermectin reduced risk of death compared with no ivermectin
Meta-analysis of 15 trials (n = 2,438)
Average risk ratio 0.38
Moderate-certainty evidence
(Confirmed using DerSimonian–Laird method and Biggerstaff–Tweedie method)
Ivermectin verses no ivermectin in hospital patients
Ivermectin, 2.3%
No ivermectin, 7.8%
Ivermectin prophylaxis reduced COVID-19 infection
3 trials, n = 738
Average reduction 86%
Low-certainty evidence
(due to study design limitations and few included trials)
Clearly favored ivermectin use
improvement
deterioration
Severe adverse events
Rare among treatment trials
Evidence of no difference was assessed as low certainty
Conclusions
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin.
Using ivermectin early in the clinical course may reduce numbers progressing
to severe disease.
The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Current NIH recommendations
https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/
there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19
The sample size of most of the trials was small
Various doses and schedules of ivermectin were used
Some of the randomized controlled trials were open-label
Patients received various concomitant (confounding) medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids)
The severity of COVID-19 in the study participants was not always well described
The study outcome measures were not always clearly defined
Ivermectin for preventing and treating COVID‐19 (April, 2021)
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017/full?highlightAbstract=ivermectin%7CcovidShow More
Dr. Paul Marik Discusses Ivermectin and Vitamin D
Please read and agree to the disclaimer before watching this video. . ...
Ivermectin prophylactic study from India
Ivermectin in India, Prophylactic role of ivermectin in SARS-CoV-2 ...
Ivermectin in India, Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers
https://www.aiims.edu/en.html
https://assets.researchsquare.com/files/rs-208785/v1/d6ff79a3-d354-4aba-a6b0-4bc123bbd225.pdf
https://www.researchsquare.com/article/rs-208785/v1
Background
Healthcare workers (HCWs) are vulnerable to getting infected withSARS-CoV-2
Preventing HCWs from getting infected is a priority to ...maintain healthcare services
The therapeutic and preventive role of ivermectin in COVID-19 is being investigated
Based on promising results of in vitro studies of oral ivermectin,
this study to look at prophylactic role of oral ivermectin
Methods
Prospective cohort study was conducted at AIIMS Bhubaneswar
Two-doses of oral ivermectin, 300 μg/kg at a gap of 72 hours
Primary outcome, COVID-19 infection in the month following
Of 3892 employees,
3532 (90.8%) participated in the study
Ivermectin uptake n = 2, 384 (67.5%)
Non uptake, n = 1147 (32.5%)
Results
Development of symptomatic infection
331 participants, developed symptoms
131 in takers
200 from non takers
Ivermectin takers, 6%
Non takers, 15%
Testing positive, 201
Ivermectin takers, 2%
Non takers, 11.7%
Implications for transmission
HCWs who had taken two-doses
(Single dose did not reach significance)
Significantly lower risk of contracting COVID-19 disease during the following month was 0.18
Adjusted Relative Risk 0.17
1.8% reported adverse events, mild and self-limiting
Conclusion and relevance
Two-doses of oral ivermectin (300 μg/kg given 72 hours apart) as chemoprophylaxis among HCWs
reduces the risk of COVID-19 infection by 83% in the following month.
Safe, effective, and low-cost chemoprophylaxis have relevance in the containment of pandemic
alongside vaccine.
https://www.pharmaceutical-technology.com/news/aiims-study-covid-19/
AIIMS Director, Gitanjali Batmanabane
Earlier, at least 20 to 25 HCWs were getting infected with the virus daily.
After the workers started taking ivermectin, the number of infection has come down to one or two per day
Critique
The safety of the drug has been established by its large-scale use in the last four decades for
various indications such as onchocerciasis, scabies, head lice, and other parasitic infestations
https://www.facebook.com/john.l.campbell1/
https://healthfeedback.org/claimreview/ivermectin-isnt-a-highly-effective-drug-for-treating-covid-19-tess-lawrie/?fbclid=IwAR2ahWjmOXuMx2u6FKgF9wTCESwHtN9EXKiKsTWCOoAygBb_P5thfAyOilAShow More
Bret and Heather 87th DarkHorse Podcast Livestream: We Must Drive this Virus to Extinction
Odysee Link: https://odysee.com/@BretWeinstein:f/EvoLens87:1 In this ...
Odysee Link: https://odysee.com/@BretWeinstein:f/EvoLens87:1
In this 87th in a series of live discussions with Bret Weinstein and Heather Heying (both PhDs in Biology), we discuss the state of the world through an ...evolutionary lens.
In this episode, we discuss why SARS-CoV2 must be driven to extinction, why the currently available vaccines are unlikely to be able to do so, and why we therefore need additional tools in our toolkit. We address and rebut the recent Quillette article, which contained copious journalistic and scientific errors, and excluded evidence relevant to the questions under discussion. A written response will be published soon as well. Finally, we share an excerpt from A Hunter-Gatherer’s Guide to the 21st Century, chapter 4 (Medicine).
Get your Goliath shirts right here: store.darkhorsepodcast.org
Our book, A Hunter-Gatherer’s Guide to the 21st Century, is now available for pre-sale at amazon. Publication date: 9-14-21: https://www.amazon.com/dp/0593086880/ref=cm_sw_r_tw_dp_5BDTABYFKRJKZBT5GSQA
http://huntergatherersguide.com/
DarkHorse merchandise now available at: store.darkhorsepodcast.org
Find more from us on Bret’s website (https://bretweinstein.net) or Heather’s website (http://heatherheying.com).
Become a member of the DarkHorse LiveStreams, and get access to an additional Q&A livestream every month. Join at Heather's Patreon.
Like this content? Subscribe to the channel, like this video, follow us on twitter (@BretWeinstein, @HeatherEHeying), and consider helping us out by contributing to either of our Patreons or Bret’s Paypal.
Looking for clips from #DarkHorseLivestreams? Here are some, updated frequently: @DarkHorse Podcast Clips
Theme Music: Thank you to Martin Molin of Wintergatan for providing us the rights to use their excellent music.
Q&A Link: https://odysee.com/EvoLens87QandA:853684e3ed57a64cbbf22d386c9a103358d5899b
Timestamps:
00:00 Welcome and announcements
03:39 Quillette article introduction
05:11 It's not the box, it's the business model
08:36 Traditional vaccines and pills
13:01 Design failures of COVID vaccines
16:01 Perverse incentives of vaccine manufacturers
19:14 Prophylaxis Vs treatments and corporate responsibility
28:50 Bad Pharma and money in big science
36:10 Scientific errors in Quillette article
39:14 Prophylaxis Vs treatments Quillette confusion
41:40 Argentinean prophylaxis study
01:00:01 Other evidence for prophylaxis in Tess Lawrie's paper and in India and Africa
01:09:45 Randomised controlled trials and mortal rigor
01:12:50 Extended Use Authorization
01:13:55 Pro vaccine and anti im
01:17:02 Safety record of im
01:28:40 Vaccine deaths being reported as COVID deaths
https://www.researchgate.net/publication/352837543_Analysis_of_COVID-19_vaccine_death_reports_from_the_Vaccine_Adverse_Events_Reporting_System_VAERS_Database_Interim_Results_and_Analysis
01:31:41 Bells palsy and outdated "fact checks"
01:40:40 Chapter 4 excerpt
01:48:08 Wrap upShow More
Ivermectin, Mexico, Peru, India
Ivermectin and the odds of hospitalization due to COVID-19: evidence ...
Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City
https://osf.io/preprints/socarxiv/r93g4/
Case study: Policy intervention in Mexico City
Increase in COVID-19 ...cases and with critical levels of hospital saturation during December 2020
Mexico City Government decided to expand population-based health
Interventions
Implementation of a prehospital home-care program
Combining early detection with antigen tests
230 kiosks
Phone-based follow up for positive patients
Since 28 December, 2020, medical ivermectin kits have been provided to positive mild to moderate symptomatic patients
Dyspnea, chest pain or cyanosis, referred to a hospital
Ivermectin, four 6mg tablets, two pills for two days
After one month, 83,000 medical kits delivered
Detailed data was collected on the evolution of patient illnesses
Quasi-experimental evaluation of the effects of the medical kits on
hospitalization
Kit receivers and non-kit receivers
Matched observations, adjusting by age, sex, COVID severity, and comorbidities
Controls, N = 156,468 patients with COVID-19 infection before implementing the ivermectin program
Experimental group, n = 77,381 after the implementation
Outcome variable: whether or not the person was hospitalized
Results
Negative and significant effect of the ivermectin-based medical kit on
the probability of hospitalization
Effect ranges from 50% to 76%
Difference in hospitalization odds between treated and untreated patients, statistically significant in all cases
As expected, the effect of the medical kits is higher and stronger among males, in older patients, and in cases without severe symptoms
Discussion and limitations
we found that the medical kit given en masse to patients who’d tested positive in Mexico City had a negative, significant, and robust effect on their odds of being hospitalized.
Independently of the medical telephone follow, level of hospital occupancy, specific period of time
Similar trend, Perú (Chamie-Quintero Et Al, 2021).
Principal mechanisms, reduction of viral load, in the patients that take ivermectin in early stages of the disease
Chamie-Quintero Et Al, 2021, Peru
https://osf.io/9egh4
25 states of Peru
Grouped by extent of IVM distributions
Maximal, medium, minimal
Reductions in excess deaths (30 days after peak deaths)
maximal, 74%
medium, 53%
minimal, 25%
Reduction of excess deaths is correlated with extent of IVM distribution by state p less than 0.002
This strongly suggests that IVM treatments can likewise effectively complement immunizations to help eradicate COVID-19.
The indicated biological mechanism of IVM,
competitive binding with SARS-CoV-2 spike protein,
is likely non-epitope specific,
possibly yielding full efficacy against emerging viral mutant strains.
Uttar Pradesh
https://indianexpress.com/article/cities/lucknow/uttar-pradesh-government-says-ivermectin-helped-to-keep-deaths-low-7311786/
Uttar Pradesh government, first to have introduced a large-scale “prophylactic and therapeutic” use of Ivermectin
Helped the state to maintain a lower fatality and positivity rate as compared to other states
Health Department introduced Ivermectin as prophylaxis for close contacts of Covid patients, August 6, 2020
Agra, Dr Anshul Pareek and State Surveillance Officer Vikssendu Agrawal
Administered Ivermectin to all RRT team members in Agra
None of them developed Covid-19
Despite being in daily contact
Despite being the state with the largest population base and a high population density, we have maintained a relatively low positivity rate and cases per million of population
Lower positivity and fatality rates may be attributed to the large-scale use of Ivermectin use UPShow More
Ivermectin discussion with Dr Tess Lawrie
Therapeutics and COVID-19: living guideline (WHO) ...
CATalyst | Ivermectin: Indian Bar Association Serve Legal Notice on WHO's Chief Scientist
Join the Conversation! | https://trialsitenews.com/ In the first ...
Join the Conversation! | https://trialsitenews.com/
In the first edition of CATalyst, Shabnam Palesa Mohamed engages Advocate Dipali Ohja (IBA), Dr Pierre Kory (FLCCC), and Dr Tess Lawrie (EBMC) about the Indian ...Bar Association's decision to issue legal notice on WHO chief scientist, Dr Soumya Swaminathan. The 51 page notice, served 25th of May, claims as its legal basis alleged WHO's 'disinformation and censorship' on the Ivermectin issue.
#CATalyst #TrialSiteNews #TrialSiteNewsAfrica #TSNAShow More
Beyond The Roundup | First EU Nation To Approve Ivermectin For Covid-19
Slovakia Becomes the First EU Nation to Formally Approve Ivermectin ...
Slovakia Becomes the First EU Nation to Formally Approve Ivermectin for Both Prophylaxis and Treatment for COVID-19 Patients:
The Slovakia Republic’s Minister of Health has formerly registered Ivermectin as an approved ...prophylaxis and treatment for SARS-CoV-2, the virus behind COVID-19. In breaking news, the authorization occurred as doctors received the news that they could proceed with formally authorized prescriptions both in hospitals and outpatient. On January 26, Health Minister Marek Krajci granted a permit for the unregistered drug as the drug has already been in use on a compassionate basis over the past half year. TrialSite interviewed Ondrej Halgas, a researcher from University of Toronto and originally from Slovakia. Halgas has been actively involved with a network organizing and lobbying for the drug’s approval during the pandemic.
https://trialsitenews.com/slovakia-becomes-the-first-eu-nation-to-formally-approve-ivermectin-for-both-prophylaxis-and-treatment-for-covid-19-patients/Show More
Vaccination and ivermectin
Novavax, 14th June, NVX-CoV2373 ...
Novavax, 14th June, NVX-CoV2373
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and
https://novavax.reportablenews.com/pr/novavax-covid-19-vaccine-19-demonstrates-90-overall-efficacy-and-100-protection-against-moderate-and-severe-disease-in-prevent-19-phase-3-trial
Recombinant nanoparticle protein-based COVID-19 vaccine
Soapbark tree
Influenza and HPV
Fridge, 2 doses, 3 week gap
Placebo-controlled, double blind, randomized 2:1
100% protection against moderate and severe disease
All hospitalizations and deaths ...in placebo group
90.4% efficacy overall
91% efficacy in high-risk populations
(over 65 or comorbidities)
N = 29,960, 119 sites, U.S. and Mexico
File for regulatory authorizations in the third quarter
100 million doses per month, then 150 million per month by end of 2021
UK, with GlaxoSmithKline, 60 million doses, Barnard Castle
Results: Consistent, high efficacy among circulating variants
77 infections
Placebo group, 63
Ten moderate cases and four severe
Vaccine group, 14 in the vaccine group
All cases observed in the vaccine group were mild
January 25 through April 30, 2021
Alpha (B.1.1.7) variant, became the predominant strain in the U.S
100% efficacy against variants not considered VoC/Vo
Favorable safety profile
Generally well-tolerated
Serious and severe adverse events few, balanced between vaccine and placebo groups
Injection site pain and tenderness, generally mild to moderate, lasting less than 3 days
Fatigue, headache and muscle pain, lasting less than 2 days
The placebo-controlled portion of PREVENT-19 continues in
Adolescents, 12 to 18 years of age
Completed enrolment, n = 2,248
Operation Warp Speed, awarded Novavax $1.6 billion contract for 100 million future doses
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Sheba Medical Center, and Tel Aviv University
Ivermectin is an FDA-approved broad spectrum anti-parasitic agent
Initially approved in humans in 1987
Nobel prize of Medicine in 2015
With its high safety profile, ivermectin is a potential treatment against COVID-19 in its different stages.
https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
To assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection
Double blinded randomized control trial
Patients receiving ivermectin 0·2 mg/kg for 3 days vs placebo
Non-hospitalized COVID-19 patients
RT-PCR, recruitment and then every two days
Primary endpoint was reduction of viral-load on the 6th day
As reflected by Ct level more than 30 (non-infectious level)
Primary outcome was supported by determination of viral culture viability
Results
N = 89
Ivermectin group, 47
Placebo group, 42
Females, 21·6%
Asymptomatic at recruitment, 16.8%
Symptomatic, 83%
On day 6
Ivermectin group
34 out of 47 (72%) reached the endpoint, (non-infectious level)
Placebo group
21 out of 42 (50%) reached the endpoint, (non-infectious level)
Odds of a negative test at day 6 was 2.62 time higher in the ivermectin group
Also
Ivermectin group, cultures at days 2 to 6 were positive in 3/23 (13·0%)
Placebo group, cultures at days 2 to 6 were positive in 14/29 (48·2%)
(p=0·008)
3 hospitalisations, 3 in the placebo group
Diarrhoea, 2 and 1
No other adverse effects were reported
Conclusions
There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.Show More
Ivermectin advised for India
WHO, India VOC, global concern https://www.who.int ...
WHO, India VOC, global concern
https://www.who.int
https://www.bbc.co.uk/news/world-asia-india-57067190
Same status as UK, South Africa and Brazil
Spreads more easily than other variants
Required more study
More than 30 countries
May be some evidence of reduced neutralization
India
Link between variant ...and second wave
Cases, + 366,161
Deaths, + 3,754
Andhra Pradesh, 11 deaths overnight, oxygen tanker delayed
Under reported deaths
https://www.dw.com/en/india-bodies-of-suspected-covid-19-victims-wash-up-on-ganges-riverbanks/a-57489467
https://www.bbc.co.uk/news/world-asia-india-56969086
11th April, Ahmedabad, 69 body bags, 20 deaths reported
16th April, visited 21 cremation grounds, 200 bodies, 25deaths reported
5th May, 500, 83
Gujarat, possibly x 10
35 – 40 bodies recovered from Ganges in Bihar, from Uttar Pradesh
Vaccination
Two doses, 34.8 million (2.5%)
Joint Statement on Widespread Use of Ivermectin in India for Prevention and Early Treatment
https://covid19criticalcare.com
https://covid19criticalcare.com/videos-and-press/flccc-releases/joint-statement-may-03-2021-joint-statement-on-widespread-use-of-ivermectin-in-india-for-prevention-and-early-treatment
The Evidence-Based Medicine Consultancy
Frontline Covid Critical Care Alliance
British Ivermectin Recommendation Development (BiRD) panel
Re-purposed existing drugs
Ivermectin, a safe medicine which has been used for nearly 40 years to treat parasitic infections
3.7 billion people have been treated with Ivermectin for parasitic infections and it has been found to be extremely safe
New evidence shows that it has potent antiviral and anti-inflammatory properties as well
urge the Indian Government and all states in India to adopt Ivermectin as a matter of urgency as a front line prophylaxis and treatment for Covid-19
All India Institute of Medical Sciences and Indian Council of Medical Research have urgently responded with a recommendation to use Ivermectin in mild outpatient illness
We also recommend that Ivermectin be used as covid-19 prophylaxis
on a large scale through mass distribution of Ivermectin in the dose of 0.2mg/kg (12mg for a 60 kg person)
weekly to adults to decrease transmission amongst the general population in the current crisis
We believe this will save thousands of lives and reduces the suffering of millions.
Dr. Tess Lawrie, Dr Shashikanth Manikappa, Dr Pierre Kory
Mucormycosis
https://www.cdc.gov/fungal/diseases/mucormycosis/index.html
https://emedicine.medscape.com/article/222551-overview
Mucor mould
Typically, 2 weeks after recovery
Stuffy and bleeding nose
Periorbital swelling and pain in the eye
Drooping of eyelids
Blurred vision leading to loss of vision
Black discharge from the nose
Prevent
Manage diabetes
Correct use and monitoring of steroids
Manage blood sugar throughout treatment
Treat
Anti-fungal intravenous injection
3,500 rupees ($48) a dose
Administered every day up to eight weeks
Dr Hegde, Bengaluru
The strain of the virus appears to be virulent, sending blood sugars soaring to very high levels.
And strangely, the fungal infection is affecting a lot of young people
Nepal
https://www.dw.com/en/covid-19-special-nepal-struggles-to-cope-as-cases-surge/av-57487346
Airport closed
Migrant workers return from India
Cases increased in border towns first
Already circulating in Kathmandu valley
Valley has remained an epicentre
Then half a million left on same day
PM advocated herbal cures
Political rallies, religious festivals, massive weddings
57 times more daily cases than last month
Patients treated outside hospitals
Indian COVID, Philippines
https://www.dw.com/en/coronavirus-digest-indian-covid-variant-reaches-philippines/a-57490707
Returning workers from UAE and Oman
Nigeria
Population 200 million
Vaccine deliveries down
4 million doses arrived so far
Johnson & Johnson arriving later this year
Poor compliance
https://www.theguardian.com/world/live/2021/may/11/coronavirus-live-news-india-variant-of-concern-globally-says-who-pfizer-vaccine-approved-for-us-12-15-year-olds
Government reimposed some lockdown restrictions
Very limited testing, unreported numbersShow More
UPDATE
As predicted, new and highly publicized RCTs “prove” IVM is ineffective. Interestingly, they were touted in the press before peer review or publication. These studies are wrought with conflicts of interest, funded by Gates Foundation and Oxford, the biggest profiteers of vaccines.
Full data is not available yet, but McMaster’s Mills’ study intially planned a single dose of Ivermectin, and appears to introduce it at 7-10 days after positive test, the exact opposite of the protocols used in all successful studies, hence, no effect.
While FLCCC is concerned that Delta’s viral load may call for increasing IVM dosage to twice per week, Tokyo’s Chief Medical Officer is calling for all out IVM campaign to stop their surge.
BUY OUR MERCH
WE’LL DO THE RESEARCH
